Meet Our Presidents: Ambra Pozzi YouTube video by ASMB - American Society for Matrix Biology

Say hello to Ambra Pozzi, PhD 🧬
Past President of the #ASMB, whose leadership helped shape the community we celebrate in our #ASMB2025 interview series.

🎥 Watch the full interview: youtu.be/7Ys0rsieCiE

#MEETTHEPRESIDENTS #ECM #MATRIXBIOLOGY

Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates Assembly Biosciences (Nasdaq: ASMB) reported Q3 2025 results and program updates on Nov 10, 2025. Key clinical highlights include positive Phase 1b interim results for ABI-5366 showing significant reductions in HSV-2 shedding and genital lesions, and Phase 1a data for ABI-6250 supporting once-daily dosing and progression to Phase 2. Enrollment completed for ABI-5366 and two ABI-1179 cohorts; an HSV data readout is now expected by year-end and a Phase 2 start for ABI-5366 is anticipated mid-2026.Financials: the company raised $175M in equity, held $232.6M cash at Sept 30, 2025 (runway into late 2027), reported Q3 revenue from Gilead collaboration of $10.8M, R&D $16.6M, and net loss of $9.2M.

#ASMB Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates

www.stocktitan.net/news/ASMB/assembly-biosc...

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting® Assembly Biosciences (Nasdaq: ASMB) presented positive Phase 1b data for its next‑generation capsid assembly modulator ABI‑4334 at AASLD The Liver Meeting® on Nov 7, 2025.The randomized, blinded Phase 1b evaluated oral once‑daily 150 mg and 400 mg doses for 28 days in predominantly HBeAg‑negative chronic hepatitis B patients. ABI‑4334 was reported as well tolerated at both doses, produced multi‑log declines in HBV DNA and pgRNA, and achieved exposures multiple‑fold above levels anticipated to inhibit cccDNA formation. As expected for the population and short dosing interval, no reductions in HBsAg were observed. Under a collaboration, Gilead has a post‑study option to obtain an exclusive license for further development of ABI‑4334.

#ASMB Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®

www.stocktitan.net/news/ASMB/assembly-biosc...

Behind Our Science Our podcast promotes novel scientific research communication in an easily digestible and fun environment to all audiences. Sponsored by the ASIP and HCS Producers and co-host: Roberto Mota Alvidrez D...

Check out the latest #BehindOurScience podcast featuring an insightful conversation between Dr. Daisy Shu & our very own ASMB Communication & Outreach Committee member, Dr. Jingjing You, a leading corneal bioengineer 👁️🧬

www.youtube.com/@behindoursc...

#ScienceCommunication #ASMB #HCS #ASIP

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings Assembly Biosciences (Nasdaq: ASMB) has announced the pricing of two equity financings totaling $175 million. The company is conducting an underwritten public offering of 5,591,840 shares of common stock and 1,040,820 pre-funded warrants, along with accompanying Class A and Class B warrants, at $19.60 per share.Additionally, Gilead Sciences will participate through a private placement, purchasing 2,295,920 shares with accompanying warrants. Notable investors include Commodore Capital, Blackstone Multi-Asset Investing, Farallon Capital Management, Janus Henderson Investors, and RA Capital Management. The transactions are expected to close on August 11, 2025.

#ASMB Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

www.stocktitan.net/news/ASMB/assembly-biosc...

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus Assembly Biosciences (Nasdaq: ASMB) has reported promising interim Phase 1a data for ABI-6250, their oral hepatitis delta virus (HDV) entry inhibitor candidate. The study demonstrated a four-day half-life, supporting once-daily oral dosing, and showed dose-dependent elevations in total serum bile acids, indicating effective target engagement.Key findings include successful completion of two single-dose cohorts (5mg and 25mg) and three multiple-dose cohorts (0.05mg, 0.2mg, and 1mg). Safety data showed mostly Grade 1 adverse events, with one Grade 2 ALT elevation in the highest dose cohort. All ALT elevations were self-limited without signs of liver injury.The company plans to conduct additional pharmacological assessment while preparing for Phase 2 studies, positioning ABI-6250 as potentially the first oral therapy for chronic HDV infection.

#ASMB Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

www.stocktitan.net/news/ASMB/assembly-biosc...

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates Assembly Biosciences (NASDAQ: ASMB) reported Q2 2025 financial results and clinical progress across its viral disease pipeline. The company ended Q2 with $75.0 million in cash, projecting operations funding into mid-2026. Revenue from Gilead collaboration increased to $9.6 million, while net loss improved to $10.2 million ($1.33 per share).Key clinical developments include: positive Phase 1b results for ABI-4334 in chronic HBV patients, interim data from ABI-6250's Phase 1a study showing target engagement for HDV treatment, and advancement of ABI-5366 and ABI-1179 trials for genital herpes, with proof-of-concept data expected by fall 2025. The company initiated U.S. site expansion for ABI-1179's Phase 1b trial following IND clearance.

#ASMB Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

www.stocktitan.net/news/ASMB/assembly-biosc...

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop Assembly Biosciences (NASDAQ:ASMB) presented Phase 1a clinical data for two novel herpes simplex virus (HSV) treatments, ABI-5366 and ABI-1179, at the STI & HIV 2025 World Congress and International Herpesvirus Workshop. The drug candidates, designed as helicase-primase inhibitors, demonstrated promising safety and pharmacokinetic profiles in healthy participants.Key highlights include the potential for once-weekly dosing for both treatments, and once-monthly dosing for ABI-5366, representing a significant improvement over current daily dosing requirements. Both candidates showed no clinically significant food effects and are now advancing to Phase 1b trials, with interim proof-of-concept data expected in fall 2025.

#ASMB Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

www.stocktitan.net/news/ASMB/assembly-biosc...

Nobel Laureate Backs New $90M Biotech Startup Revolutionizing Depression and Alzheimer's Treatment Novel synapse-targeting platform enters Phase 2 trials for major depression. Backed by AbbVie and Lilly, featuring breakthrough Alzheimer's approach. See clinical data.

#ASMB Syndeio Biosciences Launches to Lead the Emerging Field of Synapse-Targeted Neurotherapeutics

www.stocktitan.net/news/ASMB/syndeio-biosci...

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates Assembly Biosciences (NASDAQ: ASMB) reported Q1 2025 financial results and updates on its antiviral portfolio. The company ended Q1 with $91.0 million in cash, projecting operations funding into mid-2026. Revenue from Gilead collaboration increased to $9.4 million, up from $5.8 million in Q1 2024. Net loss was $8.8 million ($1.17 per share), improved from $9.1 million in Q1 2024. Key clinical developments include: - Interim Phase 1b data expected in fall 2025 for ABI-5366 and ABI-1179 in recurrent genital herpes - Phase 1a data for HDV candidate ABI-6250 expected in Q3 2025 - Phase 1b data for HBV candidate ABI-4334 expected in H1 2025 The company presented new data at multiple conferences (ICAR, ESCMID, EASL 2025) and has upcoming presentations at the Jefferies Healthcare Conference and STI & HIV World Congress.

#ASMB Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

www.stocktitan.net/news/ASMB/assembly-biosc...

ASMB President Ambra Pozzi and Executive Director Kendra LaDuca are in Portland for the #ASIP2025 meeting @asipath.bsky.social! 🎉 Today, Ambra presents on the Role of Collagen Binding Receptors in Acute Kidney Injury—exciting science from the ASMB community! 🔬🧬 #KidneyResearch #ECM #ASMB

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights Assembly Biosciences (ASMB) reported its financial results for 2024, highlighting progress across its antiviral pipeline. The company ended 2024 with $112.1 million in cash, projecting operations funding into mid-2026. Revenues increased to $28.5 million from $7.2 million in 2023, while net loss decreased to $40.2 million ($6.69 per share) from $61.2 million in 2023.Key clinical developments include positive Phase 1a interim data for ABI-1179 for recurrent genital herpes, supporting once-weekly oral dosing. The company's ABI-4334 for chronic HBV infection showed promising results with a 2.9 log10 IU/mL mean decline in HBV DNA. ASMB initiated Phase 1a study for ABI-6250 for hepatitis delta virus and advanced ABI-7423 into IND/CTA-enabling studies.The company received a $20.1 million equity investment and $10 million in accelerated funding from Gilead Sciences to advance clinical development programs.

#ASMB Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

www.stocktitan.net/news/ASMB/assembly-biosc...

We are excited to be at #ASMB in beautiful Gainesville. Chris is looking forward to catching up with everyone this week! #UFMyology

Join us for the Intersection of Women’s Health and the ECM @amsocmatbio.bsky.social e-Symposium! Don't miss this opportunity to hear the groundbreaking research from the selected speakers.🔗 Register now: www.asmb.net/e-symposia

#ECM #WomensHealth #ASMB @gpfatlab.bsky.social

We #ASMB stand up for #science on March 7 2025 - Because science is for and impacts everyone!

Find your local rally site and other ways to get involve here: standupforscience2025.org

#ECMatrixIsEverywhere #StandUpForScience2025 #ScienceNotSilence #ScienceForAll

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus Assembly Biosciences (ASMB) has initiated dosing in a Phase 1a clinical trial for ABI-6250, their oral hepatitis delta virus (HDV) entry inhibitor candidate. The study will evaluate safety, tolerability, and pharmacokinetics across single and multiple ascending dose cohorts in healthy participants, with data expected in Q3 2025.The trial will monitor serum bile acids as a biomarker of ABI-6250's engagement with its target, the NTCP transporter. Currently, only one therapy is approved for chronic HDV infection in the EU, requiring daily injections, with no approved treatments in the US.In preclinical studies, ABI-6250 has shown low nanomolar potency across multiple HDV genotypes, selectivity for NTCP versus other bile acid transporters, and a pharmacokinetic profile supporting once-daily oral dosing. Chronic HDV is considered the most severe form of viral hepatitis, with 70% of patients progressing to cirrhosis within 10 years.

#ASMB Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

www.stocktitan.net/news/ASMB/assembly-biosc...

Submit your abstracts to the Intersection of Women’s Health and the ECM @amsocmatbio.bsky.social e-symposia, deadline this Friday February 14, 12pm EST. Act fast—time is running out! #ECMSymposium #WomensHealth #ASMB @gpfatlab.bsky.social

@gpfatlab.bsky.social and I are excited to organize the next @amsocmatbio.bsky.social e-symposia focused on the "Intersection of Women’s Health and the ECM" on March 26. Short talks will be selected from abstracts. Join us #womenshealth #ECM #ASMB
www.asmb.net/e-symposia

Assembly Bio's ABI-4334 Shows Strong HBV Antiviral Activity in Phase 1b Trial - 2.9 Log DNA Reduction Assembly Biosciences reports promising interim data for ABI-4334 in chronic hepatitis B treatment, achieving significant viral reduction with favorable safety profile in Phase 1b study.

#ASMB Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

www.stocktitan.net/news/ASMB/assembly-biosc...

Breaking News: ( NASDAQ: #ASMB ) Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs

#StockMarket #News

Assembly Bio Secures $30.1M Gilead Investment, Advancing Ambitious Antiviral Pipeline Assembly Biosciences receives strategic $30.1M investment from Gilead Sciences, extending cash runway to 2026 and accelerating development of four antiviral candidates.

#ASMB Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs

www.stocktitan.net/news/ASMB/assembly-biosc...

Today, we celebrate #GivingTuesday, a day to support people and organizations, like #ASMB, that do transformative work in their communities & the world. Let #ASMB be your community and empower us to improve the human condition by making a gift to today!
👉https://asmb.net/donate-to-asmb2

#ECMatrix is everywhere and in everything! So please keep #ASMB in mind when you consider #givingtuesday2024

More info 👉 asmb.memberclicks.net/donate-to-as...

Our very own #ASMB Secretary/Treasurer Dr. Karen LaShea Posey from McGovern Medical School at UT Health is #ASMBeThankful for the beautiful #Diversity of #Science and #Nature!

What are you #ASMBeTHANKFUL for?

Mark your calendars!!!

#ASMB 2025 Biennial Meeting👇🏻
🗓️When? November 16-19, 2025
🏙️Where? Baltimore
🥅What? #ECMatrix #Marvels
❓Why? 25th anniversary with lots of new features 🥳 plus all the leading #ECMatrix research (and we all know how fundamental it is to life!)

BREAKING NEWS: ( NASDAQ: #ASMB ) (ASMB) Pivots Trading Plans and Risk Controls

#StockMarket #News

Consciência Negra: Ação Social pela Música promove eventos de graça Para marcar o Dia da Consciência Negra a Ação Social pela Música do Brasil (ASMB) promove uma série de atividades de graça. Saiba mais!

#consciencianegra e #asmb : viventeandante.com/acao-social-...

BREAKING NEWS: ( NASDAQ: #ASMB ) Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

#StockMarket #News